Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / MRK - Merck Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial This Time In Endometrial Cancer | Benzinga

MRK - Merck Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial This Time In Endometrial Cancer | Benzinga

Merck & Company Inc.

Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pembrolizumab) plus Lenvima (lenvatinib) did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) as first-line treatment for patients with advanced or recurrent endometrial carcinoma.

The trial included patients with advanced or recurrent endometrial carcinoma whose disease is mismatch repair proficient (pMMR)/not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)/MSI-H.

Also Read: Full story available on Benzinga.com
Stock Information
Company Name: Merck & Company Inc.
Stock Symbol: MRK
Market: NYSE
Website: merck.com
Menu
MRK MRK Quote MRK Short MRK News MRK Articles MRK Message Board
Get MRK Alerts

News, Short Squeeze, Breakout and More Instantly...